WallStreetZenWallStreetZen

NASDAQ: SKYE
Skye Bioscience Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SKYE

Based on 2 analysts offering 12 month price targets for Skye Bioscience Inc

Min Forecast
$14.00+582.93%
Avg Forecast
$14.50+607.32%
Max Forecast
$15.00+631.71%

Should I buy or sell SKYE stock?

Based on 2 analysts offering ratings for Skye Bioscience Inc.

Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although SKYE's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates SKYE as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their SKYE stock forecasts and price targets.

SKYE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-21
lockedlocked$00.00+00.00%2025-03-21

1 of 1

Forecast return on equity

Is SKYE forecast to generate an efficient return?

Company
-127.07%
Industry
140.91%
Market
90.47%
SKYE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SKYE forecast to generate an efficient return on assets?

Company
-116.2%
Industry
32.45%
SKYE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SKYE earnings per share forecast

What is SKYE's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$1.31
Avg 2 year Forecast
-$1.56
Avg 3 year Forecast
-$2.00

SKYE revenue forecast

What is SKYE's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$18.0M

SKYE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SKYE$2.05$14.50+607.32%Buy
VTGN$2.21N/AN/A
RPTX$1.47$5.00+240.83%Buy
RENB$0.37N/AN/A
ADAP$0.24$1.52+528.93%Hold
View Top Biotech Stocks

Skye Bioscience Stock Forecast FAQ

Is Skye Bioscience Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: SKYE) stock is to Buy SKYE stock.

Out of 2 analysts, 0 (0%) are recommending SKYE as a Strong Buy, 2 (100%) are recommending SKYE as a Buy, 0 (0%) are recommending SKYE as a Hold, 0 (0%) are recommending SKYE as a Sell, and 0 (0%) are recommending SKYE as a Strong Sell.

If you're new to stock investing, here's how to buy Skye Bioscience stock.

What is SKYE's earnings growth forecast for 2025-2027?

(NASDAQ: SKYE) Skye Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Skye Bioscience's earnings in 2025 is -$32,650,911.On average, 4 Wall Street analysts forecast SKYE's earnings for 2025 to be -$40,589,509, with the lowest SKYE earnings forecast at -$46,166,693, and the highest SKYE earnings forecast at -$37,181,230. On average, 4 Wall Street analysts forecast SKYE's earnings for 2026 to be -$48,335,598, with the lowest SKYE earnings forecast at -$55,771,844, and the highest SKYE earnings forecast at -$40,589,509.

In 2027, SKYE is forecast to generate -$61,813,794 in earnings, with the lowest earnings forecast at -$80,249,487 and the highest earnings forecast at -$43,378,101.

What is SKYE's revenue growth forecast for 2029-2029?

(NASDAQ: SKYE) Skye Bioscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Skye Bioscience's revenue in 2025 is $0.

In 2029, SKYE is forecast to generate $556,788,913 in revenue, with the lowest revenue forecast at $556,788,913 and the highest revenue forecast at $556,788,913.

What is SKYE's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: SKYE) forecast ROA is -116.2%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is SKYE's Price Target?

According to 2 Wall Street analysts that have issued a 1 year SKYE price target, the average SKYE price target is $14.50, with the highest SKYE stock price forecast at $15.00 and the lowest SKYE stock price forecast at $14.00.

On average, Wall Street analysts predict that Skye Bioscience's share price could reach $14.50 by Mar 21, 2026. The average Skye Bioscience stock price prediction forecasts a potential upside of 607.32% from the current SKYE share price of $2.05.

What is SKYE's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: SKYE) Skye Bioscience's current Earnings Per Share (EPS) is -$0.83. On average, analysts forecast that SKYE's EPS will be -$1.31 for 2025, with the lowest EPS forecast at -$1.49, and the highest EPS forecast at -$1.20. On average, analysts forecast that SKYE's EPS will be -$1.56 for 2026, with the lowest EPS forecast at -$1.80, and the highest EPS forecast at -$1.31. In 2027, SKYE's EPS is forecast to hit -$2.00 (min: -$2.59, max: -$1.40).

What is SKYE's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: SKYE) forecast ROE is -127.07%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.